CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

Trial Details

NCT ID

NCT07366112

Phase

PHASE2

Sponsor

Peking University People's Hospital

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

• CDK4/6 inhibitor with endocrine therapy

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Female breast cancer patients aged ≥18 years and ≤75 years, either postmenopausal or premenopausal/perimenopausal; 2.Pathologically confirmed hormo…
• ER-positive and/or PR-positive defined as: ≥10% of tumor cells showing positive staining;
• HER2-negative defined as: standard immunohistochemistry (IHC) result of 0/1+; or IHC 2+ with negative in situ hybridization (ISH) (confirmed by the…
• T1c-2N0M0 with high-risk factors (Grade 3, or Grade 2 with Ki67 ≥20%);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.